• JenaValve Technology

  Participated · Series C · Sep 2022

  JenaValve designs, develops and commercializes the Trilogy Heart Valve System, a TAVR platform intended to treat symptomatic, severe aortic regurgitation (AR) and aortic stenosis (AS) in high surgical risk patients. The Trilogy System received CE Mark approval in May 2021 and is positioned as a dual‑disease treatment device. The company has received FDA Breakthrough Device Designation for ALIGN-AR to facilitate review of a pivotal U.S. trial as part of a PMA filing. JenaValve intends to use its recent financing to complete an IDE/PMA study to obtain FDA approval for Trilogy in AR patients. Proceeds will also support real‑world data development in Europe and expansion of worldwide manufacturing capabilities. The company is led by CEO John Kilcoyne and operates locations in Irvine, CA, Leeds, U.K., and Munich, Germany. JenaValve Technology develops and manufactures differentiated transcatheter aortic valve replacement (TAVR) systems, including the Trilogy® TAVR system. The Trilogy system is intended to treat patients with severe symptomatic aortic regurgitation (AR) and aortic stenosis (AS). JenaValve is conducting the ALIGN-AR PMA clinical trial (IDE approved August 2021) and reports patient enrollment remains on track as it pursues U.S. FDA approval for the Trilogy Heart Valve System. The company said the capital from the new partnership will support the ALIGN-AR trial and accelerate expansion of its current commercial activities in Europe. JenaValve is headquartered in Irvine, California, with additional locations in Leeds, U.K., and Munich, Germany. Existing backers include Bain Capital Life Sciences, Cormorant Asset Management, Andera Partners, Gimv, Legend Capital, NeoMed Management, RMM, Valiance Life Sciences, VI Partners and Peijia Medical. JenaValve develops the JenaValve Pericardial TAVR System, a self‑expanding nitinol stent with a porcine pericardial valve available in three sizes. The device is investigational and not available for sale in the U.S. or internationally. The company is conducting a global multicenter clinical program targeting severe aortic regurgitation (AR) and AR‑dominant mixed aortic valve disease in high‑risk surgical patients. JenaValve recently received Breakthrough Device designation from the U.S. FDA, which allows priority review of its Align Clinical Trial. Following completion of the Humanitarian Device Exemption (HDE) portion of the trial, enrollment will continue to support a Premarket Approval (PMA) submission under the Breakthrough program. The company also anticipates filing for CE mark approval for both aortic stenosis and aortic regurgitation in the second half of 2020. JenaValve Technology develops, manufactures and markets next-generation transcatheter aortic valve repair (TAVR) systems to treat patients with aortic valve disease. Its Transapical TAVR system (JenaValve valve plus Cathlete PLUS delivery) has CE Mark approval for aortic stenosis and the unique indication to treat aortic valve insufficiency. The company currently markets this product in Europe and selected markets worldwide and has operating locations in Munich, Germany and Irvine, California. JenaValve completed a $26.5 million Series C expansion financing to fund further growth in the global TAVR market. Proceeds will support key clinical studies required to gain European regulatory approval and to complete a U.S. feasibility study for a new aortic valve and transfemoral delivery system. The financing is positioned to help JenaValve advance its product pipeline and execute regulatory and clinical plans. JenaValve Technology develops, manufactures and markets transcatheter aortic valve implantation (TAVI) systems, including a CE‑marked transapical TAVI system currently sold in Europe and other markets. Its JenaValve prosthesis pairs a porcine bioprosthesis with a Nitinol self‑expanding stent and features a “3‑feeler element” for accurate positioning plus a JenaClip anchoring mechanism; the valve is retrievable and repositionable and implanted on the beating heart. The company’s transfemoral TAVI system entered a first‑in‑man clinical study at the end of 2013 and was anticipated to be commercially available in 2015. JenaValve positions its devices as second‑generation TAVI products aimed at easing implantation and reducing pacemaker implantation and paravalvular leakage. Financially, the company expanded its Series C by $10 million, bringing the round total to $72.5 million. JenaValve is a U.S. corporation with primary operations in Munich and was founded by cardiologists Prof. Hans R. Figulla and Prof. Markus Ferrari.

• Delenex Therapeutics

  Participated · Series A · Nov 2013

  Delenex Therapeutics AG is a privately-held biopharmaceutical company developing locally or topically applied antibody therapeutics using its proprietary PENTRA platform. The company focuses on PENTRA Bodies to deliver potent, safe antibody therapeutics for dermatologic diseases and extend benefits of antibodies to more patients. Its clinical lead is the anti-TNFα PENTRABody DLX105, currently in a phase 2a psoriasis study with data expected in mid-2014. Recent proceeds will be used to finish that phase 2a study, advance development of PENTRA Bodies toward clinical development, and exploit the PENTRA antibody and technology platform to generate novel products. Delenex is based in Schlieren and was founded in September 2009 as a spin-off from ESBATech. The company has extended its Series A financing, reflecting continued investor commitment to its dermatology franchise and pipeline. Delenex Therapeutics is a Schlieren (Zurich), Switzerland-based biotech developing therapeutic antibody fragments using its PENTRA® platform. Its core product effort includes DLX105, an anti-TNFalpha single-chain Fv antibody targeting inflammatory diseases. The company plans to bring DLX105 to proof of concept in inflammatory indications, including dermatology, and to evaluate its PENTRA antibodies against additional targets. Financially, Delenex extended its Series A by CHF16.7m ($19.3m), bringing the round total to CHF30.2m ($34.8m). The funding was led by Novo Ventures with participation from SV Life Sciences, HBM BioCapital, HBM BioVentures, BioMedInvest and VI Partners. In conjunction with the financing Novo's Thomas Dyrberg will join the board; management includes CEO Eric de La Fortelle, CSO Titus Kretzschmar and CFO Jakob Schlapbach. Delenex develops therapeutic antibody fragments targeting central nervous system, inflammatory, respiratory and dermatologic diseases. The company recently closed a CHF13.5m (≈US$14m, €10m) Series A venture capital financing. It intends to use the funding to advance its antibody fragment programs and initiate additional clinical trials in the near future. Delenex was spun out of ESBATech AG in September 2009 and has rights to further develop, apply and commercially exploit the clinically validated ESBATech antibody technology and products outside ophthalmology. The company is based in Zürich‑Schlieren, Switzerland. Management includes Thomas Hecht MD (Executive Chairman), Titus Kretzschmar PhD (Chief Scientific Officer) and Hamish Cameron MD (Business Development).

• Nexthink

  Participated · Series C · Mar 2012

  Nexthink offers a platform that continuously analyzes billions of real-time signals across devices, applications, and networks to give IT teams a comprehensive, moment-to-moment view of technology performance across the enterprise. Leveraging generative and agentic AI, the software anticipates user needs, detects and resolves issues proactively, and automates large-scale improvements. By focusing on Digital Employee Experience, the company enables organizations to boost productivity and reduce IT support costs. Nexthink currently serves more than 1,500 enterprise customers and supports 25 million employees worldwide. Headquartered in Lausanne, Switzerland, with a U.S. base in Boston, the company is led by founder and CEO Pedro Bados. The leadership team is positioned to drive the next phase of growth following the latest investment. While revenue figures were not disclosed, the customer base indicates significant market penetration and recurring usage of the platform.

• Deal United

  Led · Equity · May 2010

  deal united, established in 2008 and based in Munich, provides a payment method called PAY.BY.SHOPPING that lets customers pay for digital and virtual products by purchasing a product or voucher at the company’s shopping partners. Its merchant network includes Bigpoint, DivX, Frogster, Sony Musicbox and Steganos. The company operates in Germany, France, Great Britain and the USA and maintains offices in Paris and San Francisco. deal united closed a Series B financing round; the amount was not disclosed. Investors include new backer E-Commerce Beteiligungs GmbH and existing shareholders Bertelsmann Digital Media Investments, KFW Bankengruppe, High-Tech Gründerfonds and Venture Incubator. The company plans to use the funds to grow staff and further expand its global brand awareness. deal united GmbH operates an online marketing platform that helps online shops, software providers, social communities and browser- and online-games increase sales and conversion rates. The platform offers users digital products and virtual goods for free in return for accepting one of deal united’s premium offers, with deal united paying for the products and goods. The company’s network already includes recognized German and international brands such as OTTO, DivX, myprinting and Khan Wars. deal united has raised about €5m in equity financing from Bertelsmann Digital Media Investments and Swiss venture capital firm Venture Incubator. The capital infusion will enable the company to begin its international expansion. The financing was reported on May 20, 2010.

• CeQur Simplicity

  Participated · Series A · Jan 2010

  CeQur commercializes simple-to-use, wearable insulin-delivery devices designed to replace multiple daily injections, with CeQur Simplicity as its mealtime insulin patch offering. The company reports clinical evidence showing significantly improved A1C and time-in-range outcomes and cites studies and presentations supporting patient adherence. Adoption is expanding across primary care and endocrinology practices; the company says better than 85% of claims are covered as a pharmacy benefit with an average copay of less than $45 per month. Nearly 90% of patients reported better adherence with CeQur Simplicity versus multiple daily injections, according to cited patient-experience data. CeQur has new FDA clearances and an advancing pipeline that includes extended 7-day wear and 1-unit and 2-unit patch options. The company announced a $100 million Series E to fund commercial expansion, including growth of its field sales organization.

No current team members are available.